Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Oncol. May 10, 2013; 4(2): 29-42
Published online May 10, 2013. doi: 10.5306/wjco.v4.i2.29
Published online May 10, 2013. doi: 10.5306/wjco.v4.i2.29
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
Soley Bayraktar, Departments of Medical Oncology, Mercy Cancer Center, Ardmore, OK 73401, United States
Caio M Rocha-Lima, University of Miami and Sylvester Comprehensive Cancer Center, Miami, FL 33124, United States
Author contributions: Both authors contributed equally to this work.
Correspondence to: Soley Bayraktar, MD, MBA, Departments of Medical Oncology, Mercy Cancer Center, 1220 Hall street, Ardmore, OK 73401, United States. soley.bayraktar@mercy.net
Telephone: +1-580-5042781 Fax: +1-580-2206118
Received: March 7, 2013
Revised: April 9, 2013
Accepted: April 17, 2013
Published online: May 10, 2013
Processing time: 73 Days and 17 Hours
Revised: April 9, 2013
Accepted: April 17, 2013
Published online: May 10, 2013
Processing time: 73 Days and 17 Hours
Core Tip
Core tip: Targetable molecular abnormalities have not yet been identified in approximately 80% of non-small-cell lung cancer patients. In addition to anaplastic lymphoma kinase, epidermal growth factor receptor, vascular endothelial growth factor targeted therapies, the results from ongoing trials will determine if the newer targeted agents will be incorporated into clinical practice.